2023
The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer
Grant M, Woodard G, Goldberg S. The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 513-531. PMID: 37024389, DOI: 10.1016/j.hoc.2023.02.003.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerMetastatic non-small cell lung cancerResectable non-small cell lung cancerImmuno-oncology agentsHistologic classification systemUnited States FoodResectable tumorsSystemic therapyDriver alterationsDrug AdministrationStates FoodSystemic managementPatientsTherapyCancerEvolving roleClassification systemNTRKHER2TumorsKRASEGFRBRAFEfficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Grant M, Aredo J, Starrett J, Stockhammer P, van Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.Peer-Reviewed Original ResearchConceptsProgression-free survivalNon-small cell lung cancerInferior progression-free survivalMulticenter retrospective cohortEfficacy of osimertinibMulti-institutional cohortCell lung cancerExon 19 deletion mutationUncommon EGFRRetrospective cohortClinical outcomesClinical efficacyLung cancerOsimertinib efficacyEGFR mutationsPreclinical modelsEx19delPatientsAACR Genie databaseLater linesOsimertinibMutant cohortFirst lineCohortEfficacy
2022
Cancer of the Lung
Morgensztern D, Boffa D, Chen A, Dhanasopon A, Goldberg S, Decker R, Devarakonda S, Ko J, Soto L, Waqar S, Wistuba I, Herbst R. Cancer of the Lung. 2022, 1-29. DOI: 10.1002/9781119000822.hfcm085.pub2.Peer-Reviewed Original ResearchEP08.02-019 Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Spira A, Spigel D, Camidge R, de Langen A, Kim T, Goto K, Elamin Y, Shum E, Reckamp K, Rotow J, Goldberg S, Gadgeel S, Leal T, Albayya F, Fitzpatrick S, Louie-Gao M, Parepally J, Zalutskaya A, Yu H. EP08.02-019 Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2022, 17: s406. DOI: 10.1016/j.jtho.2022.07.701.Peer-Reviewed Original Research1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
De Langen J, Cho B, Piotrowska Z, Le X, Goldberg S, Goldman J, Okamoto I, Hewson N, Maidment J, Tang K, Veney N, Cosaert J, Lau J, Dressman M, Ambrose H, Riess J, Yu H. 1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib. Annals Of Oncology 2022, 33: s1091-s1092. DOI: 10.1016/j.annonc.2022.07.1311.Peer-Reviewed Original Research
2021
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
Yu H, Ambrose H, Baik C, Cho B, Cocco E, Goldberg S, Goldman J, Kraljevic S, de Langen A, Okamoto I, Piotrowska Z, Pluta M, Powar S, Aransay N, Riess J, Le X. 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. Annals Of Oncology 2021, 32: s978-s979. DOI: 10.1016/j.annonc.2021.08.1844.Peer-Reviewed Original Research
2019
P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy
Yu H, Goldberg S, Le X, Piotrowska Z, Smith P, Mensi I, Kirova B, Chmielecki J, Li-Sucholeicki X, Szekeres P, Doughton G, Patel G, Jewsbury P, Riess J. P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy. Journal Of Thoracic Oncology 2019, 14: s647. DOI: 10.1016/j.jtho.2019.08.1366.Peer-Reviewed Original ResearchFinal Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Campbell A, Cai W, Burkhardt D, Gettinger S, Goldberg S, Amodio M, Kaech S, Krishnaswamy S, Decker R. Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC). International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s36-s37. DOI: 10.1016/j.ijrobp.2019.06.453.Peer-Reviewed Original Research105O Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study
Ahn M, Chiu C, Cheng Y, Han J, Goldberg S, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Mendoza-Naranjo A, Mok T. 105O Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study. Annals Of Oncology 2019, 30: ii48. DOI: 10.1093/annonc/mdz063.003.Peer-Reviewed Original Research
2018
492O Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC
Ahn M, Chiu C, Cheng Y, Han J, Goldberg S, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Mendoza-Naranjo A, Mok T. 492O Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC. Annals Of Oncology 2018, 29: ix151-ix152. DOI: 10.1093/annonc/mdy425.003.Peer-Reviewed Original ResearchFinal Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.Peer-Reviewed Original ResearchFinal results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.Peer-Reviewed Original ResearchSafety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.
Garon E, Spira A, Goldberg S, Chaft J, Papadimitrakopoulou V, Antonia S, Brahmer J, Camidge D, Powderly J, Wozniak A, Felip E, Gao G, Englert J, Awad M. Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients. Journal Of Clinical Oncology 2018, 36: 9041-9041. DOI: 10.1200/jco.2018.36.15_suppl.9041.Peer-Reviewed Original ResearchDurability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.
Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.Peer-Reviewed Original ResearchMORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).
Johnson M, Solomon B, Awad M, Cho B, Gainor J, Goldberg S, Keam B, Lee D, Huang C, Helms H, Barak H, Fasso M, Bleul C, Cha E, Rizvi N. MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2018, 36: tps9105-tps9105. DOI: 10.1200/jco.2018.36.15_suppl.tps9105.Peer-Reviewed Original Research
2016
Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.
Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.Peer-Reviewed Original Research
2015
Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
Rizvi N, Chaft J, Balmanoukian A, Goldberg S, Sanborn R, Steele K, Rebelatto M, Gu Y, Karakunnel J, Antonia S. Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status. Journal For ImmunoTherapy Of Cancer 2015, 3: p193. PMCID: PMC4649434, DOI: 10.1186/2051-1426-3-s2-p193.Peer-Reviewed Original Research3086 A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC
Goldberg S, Balmanoukian A, Chaft J, Rizvi N, Sanborn R, Rebelatto M, Narwal R, Robbins P, Gu Y, Karakunnel J, Antonia S. 3086 A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC. European Journal Of Cancer 2015, 51: s627. DOI: 10.1016/s0959-8049(16)31727-0.Peer-Reviewed Original ResearchActivity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.
Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Journal Of Clinical Oncology 2015, 33: 8035-8035. DOI: 10.1200/jco.2015.33.15_suppl.8035.Peer-Reviewed Original ResearchPhase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.
Antonia S, Goldberg S, Balmanoukian A, Sanborn R, Steele K, Narwal R, Robbins P, Gu Y, Karakunnel J, Rizvi N. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. Journal Of Clinical Oncology 2015, 33: 3014-3014. DOI: 10.1200/jco.2015.33.15_suppl.3014.Peer-Reviewed Original Research